THALLIUM, THALLOUS CHLORIDE TI201 DIN 02329824
Health Canada record
| Active ingredient(s) | THALLIUM CHLORIDE(TI 201) 1 UNIT |
|---|---|
| Dosage form | Liquid |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | |
| Original market date | |
| Current status date | 29-Sep-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing THALLIUM CHLORIDE(TI 201)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02327945 | THALLIUM | LANTHEUS MI CANADA INC | Solution | THALLIUM CHLORIDE(TI 201) 2 MCI | Cancelled Post Market |
| 02327961 | THALLIUM | LANTHEUS MI CANADA INC | Solution | THALLIUM CHLORIDE(TI 201) 1 MCI | Cancelled Pre Market |
| 02485915 | THALLOUS CHLORIDE TI 201 INJECTION | GE HEALTHCARE CANADA INC | Solution | THALLIUM CHLORIDE(TI 201) 37 MBq | Cancelled Post Market |
| 02328925 | THALLOUS CHLORIDE TI-201 INJECTION | CURIUM CANADA INC | Solution | THALLIUM CHLORIDE(TI 201) 37 MBq | Dormant |